VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

To investigate the von Willebrand factor to ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma (HCC) in cirrhosis.

Methods

Serum levels of alpha-fetoprotein, des-γ-carboxy prothrombin, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (alpha-fetoprotein-L3%), vascular endothelial growth factor, and vascular endothelial growth factor receptor-2, as well as the plasma levels of von Willebrand factor antigen (von Willebrand factor: Ag) and ADAMTS13 activity (ADAMTS13:AC), were evaluated in 41 cirrhotic patients with HCC undergoing radiofrequency ablation and in 20 cirrhotic patients without HCC. The diagnostic accuracy of each biomarker was evaluated using the receiver operating characteristic curve analysis.

Results

The von Willebrand factor: Ag and von Willebrand factor: Ag/ADAMTS13:AC ratios were significantly higher in cirrhotic patients with HCC than in those without HCC ( p < 0.05 and p < 0.01, respectively), whereas ADAMTS13:AC was significantly lower in those with HCC than those without HCC (p < 0.05). However, no relationship was observed between the von Willebrand factor: Ag/ADAMTS13:AC ratio and serum tumor markers such as alpha-fetoprotein, des-γ-carboxy prothrombin, and alpha-fetoprotein-L3%. Multivariate regression analysis identified von Willebrand factor: Ag/ADAMTS13:AC ratio and alpha-fetoprotein-L3% as significant factors of HCC development. Receiver operating characteristic analysis showed that the von Willebrand factor: Ag/ADAMTS13:AC ratio and alpha-fetoprotein-L3% had a better performance than alpha-fetoprotein, des-γ-carboxy prothrombin, alpha-fetoprotein-L3%, vascular endothelial growth factor, and vascular endothelial growth factor receptor-2, von Willebrand factor: Ag, and ADAMTS13:AC. The von Willebrand factor: Ag/ADAMTS13:AC ratio was exclusively correlated with tumor volume and stage as well as serum vascular endothelial growth factor levels.

Conclusions

The von Willebrand factor: Ag/ADAMTS13:AC ratio can potentially serve as a novel biomarker for early diagnosis of HCC in cirrhotic patients.

Related collections

Most cited references 40

Record: found
Abstract: found
Article: found

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

Masatoshi Kudo, Osamu Matsui, Namiki Izumi … (2014)

The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term “lipiodol” from the definition of TACE failure/refractoriness.

0 comments Cited 247 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

A Singal, M L Volk, A Waljee … (2009)

A majority of studies investigating the accuracy of ultrasound for detecting hepatocellular carcinoma (HCC) do not reflect how this test is used for surveillance vs. diagnosis. To determine the performance characteristics of surveillance with ultrasound for the detection of HCC, particularly early HCC as defined by the Milan criteria. A systematic literature review using the MEDLINE and SCOPUS databases yielded six studies that evaluated the accuracy of ultrasound for HCC at any stage and 13 studies that were specific to early HCC. Surveillance ultrasound detected the majority of tumours before they presented clinically, with a pooled sensitivity of 94%. However, ultrasound was less effective for detecting early HCC with a sensitivity of 63%. Alpha-fetoprotein provided no additional benefit to ultrasound. Meta-regression analysis demonstrated a significantly higher sensitivity for early HCC with ultrasound every 6 months than with annual surveillance. Current studies have limitations such as verification bias and are of suboptimal quality. Surveillance with ultrasound demonstrates limited sensitivity for early HCC, although this may be improved by testing at 6-month intervals. Currently available evidence evaluating surveillance ultrasound has significant limitations and future studies are necessary to determine optimal surveillance methods for early HCC.

0 comments Cited 218 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

HCC and angiogenesis: possible targets and future directions.

Andrew Zhu, Dan G Duda, Dushyant V Sahani … (2011)

Hepatocellular carcinoma (HCC), the most common primary liver tumor, is notoriously resistant to systemic therapies, and often recurs even after aggressive local therapies. HCCs rely on the formation of new blood vessels for growth, and VEGF is critical in this process. A hallmark of new vessel formation in tumors is their structural and functional abnormality. This leads to an abnormal tumor microenvironment characterized by low oxygen tension. The liver is perfused by both arterial and venous blood and the resulting abnormal microenvironment selects for more-aggressive malignancies. Anti-VEGF therapy with sorafenib was the first systemic therapy to demonstrate improved survival in patients with advanced-stage HCC. This important development in the treatment of HCC raises hope as well as critical questions on the future development of targeted agents including other antiangiogenic agents, which hold promise to further increase survival in this aggressive disease.

0 comments Cited 200 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Hiroaki Takaya: htky@naramed-u.ac.jp

Tadashi Namisaki:

ORCID: http://orcid.org/0000-0002-3158-5318

+81-744-22-3015 , tadashin@naramed-u.ac.jp

Mitsuteru Kitade: kitadem@naramed-u.ac.jp

Kosuke Kaji: kajik@naramed-u.ac.jp

Keisuke Nakanishi: nakanishi@naramed-u.ac.jp

Yuki Tsuji: tsujih@naramed-u.ac.jp

Naotaka Shimozato: shimozato@naramed-u.ac.jp

Kei Moriya: moriyak@naramed-u.ac.jp

Kenichiro Seki: seki@naramed-u.ac.jp

Yasuhiko Sawada: yasuhiko@naramed-u.ac.jp

Soichiro Saikawa: saikawa@naramed-u.ac.jp

Shinya Sato: shinyasato@naramed-u.ac.jp

Hideto Kawaratani: kawara@naramed-u.ac.jp

Takemi Akahane: stakemi@naramed-u.ac.jp

Ryuichi Noguchi: rnoguchi@naramed-u.ac.jp

Masanori Matsumoto: mmatsumo@naramed-u.ac.jp

Hitoshi Yoshiji: yoshijih@naramed-u.ac.jp

Journal

Journal ID (nlm-ta): BMC Gastroenterol

Journal ID (iso-abbrev): BMC Gastroenterol

Title: BMC Gastroenterology

Publisher: BioMed Central (London )

ISSN (Electronic): 1471-230X

Publication date (Electronic): 21 October 2019

Publication date PMC-release: 21 October 2019

Publication date Collection: 2019

Volume: 19

Electronic Location Identifier: 167

Affiliations

[1 ]ISNI 0000 0004 0372 782X, GRID grid.410814.8, Third Department of Internal Medicine, , Nara Medical University, ; Shijo-cho 840, Kashihara, Nara, 634-8522 Japan

[2 ]ISNI 0000 0004 0372 782X, GRID grid.410814.8, Department of Blood Transfusion Medicine, , Nara Medical University, ; Kashihara, Nara, 634-8522 Japan

Author information

Tadashi Namisaki http://orcid.org/0000-0002-3158-5318

Article

Publisher ID: 1082

DOI: 10.1186/s12876-019-1082-1

PMC ID: 6802329

PubMed ID: 31638892

SO-VID: 695660e1-679d-4438-9000-2a7ffbbcc108

License:

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.